David joined GfK Bridgehead as a Principal Consultant in 2009 from Napp Pharmaceutical Group, where he was Marketing Group Brand Manager. David has pharmaceutical marketing, commercial and supply chain experience, gained over 17 years in both the Pharma and Biotech sectors. Much of his career has focused on integrating research, development and supply chain issues with commercial strategy. David has experience in a broad range of therapy areas, including pain, respiratory, inflammation, and infectious disease therapy areas.
Prior to NAPP, David was Strategic Marketing Manager at Cambridge Antibody Technology (CAT), covering strategy, evaluation, portfolio management and alliances. Before joining CAT he was Business Franchise Manager (Respiratory & Dermatology Franchise, Global Marketing) for Novartis Pharma AG based in Basel.
David started his pharmaceutical career in Glaxo, initially in manufacturing, establishing the non- CFC MDI production facility, moving to Canada as Engineering Manager with GlaxoWellcome. Later as Respiratory Manufacturing Strategy Manager, he contributed to the GSK manufacturing merger integration, as well as improving the global respiratory supply chain. Prior to moving to Basel he was Business and Commercial Analysis Manager for the Respiratory, covering valuation, forecasting, market research, LCM projects and portfolio review.
David has a MBA from Cranfield, is a Member of the Chartered Institute of Marketing, and is a Chartered Engineer with a MEng degree from Southampton University.